Business Wire

New Credit Karma Platform Brings More Personalised and In-depth Credit Guidance - Aimed to Boost Nation’s Credit Knowledge

Share

UK fintech and free credit report provider CreditKarma.co.uk has completed a radical overhaul of its web and app offering, bringing more tools and services to its members.

With the aim of educating through personalised information and actionable steps - a key new market-leading feature is that the credit score is now broken up into eight main ‘credit factors’.

Each of these factors can be explored and better understood, with the service offering practical guidance on improving these elements to ensure members can make positive financial progress.

For example, when it comes to ‘credit utilisation’ – the platform will explain that the most favourable use of credit is between 1-24% of total available credit and that anything over 75% can start to harm your score. Using this information, the platform will suggest which lines of credit to reduce first.

The seven other factors influencing user credit scores are listed as:

- Payment history
- Credit limit
- Time on electoral roll
- Historic utilisation
- Age of credit
- Mortgage
- Number of new accounts.

Members will be provided with personalised guidance on how each factor influences their score and where they can improve it.

And in contrast to other credit report providers that lead with recommended products, Credit Karma now revolves around member motivations and goals – be it boosting your credit score or improving your home. A step-by-step mini questionnaire helps members find products tailored to their financial situation.

The ability to watch for potential ID theft or similar fraud has also been given a boost with the new platform changes – with the option for push notifications to alert members if certain elements of their credit health changes or new credit agreements are detected. And members credit scores are updated every seven days – the most frequent in the market – to help customers stay on top of their financial progress.

In addition to the changes to the site and app, Credit Karma will be increasing the number of products it will offer in the coming months, to give its members even more choice.

Nichole Mustard, Co-founder and Chief Revenue Officer of Credit Karma said: “We’re being more transparent than other credit report providers, breaking up the credit score into its constituent parts and in a personalised way, helping members understand what they can do to improve their situation and get more out of their financial lives.

“We’re also talking to our members differently, compared to our competitors. We are personalising our product by focusing on the individual member’s goals they want to achieve rather than simply listing a range of financial products that might not be right for where they are in their financial journey. We believe consumers will appreciate this approach and that the new platform will enable us to help our members even more.”

About Credit Karma

Founded in 2007 by Kenneth Lin, Nichole Mustard and Ryan Graciano, Credit Karma is a personal finance technology company best known for providing more than four billion free credit scores to consumers. In 2019, the company grew its international footprint by going live in the U.K. Today, Credit Karma is the go-to destination for more than 100 million members globally — using predictive, data-driven insights to identify opportunities where consumers can make the most of their money. Whether someone is interested in getting a better rate on a credit card, looking for ways to save or simply needs to monitor their credit, Credit Karma offers actionable tools to champion financial progress for them. Learn more about how Credit Karma members are making financial progress on Facebook, Twitter, and YouTube.

The information in this statement is intended for journalists and media professionals only. The information should not be construed as a financial promotion under the Financial Conduct Authority's (FCA) Handbook of Rules and Guidance.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, please contact Third City PR:
Tabby Haysom / 020 3668 6903 / 07719939902 / Tabby@thirdcity.co.uk
Matt Hubbard / 020 3657 9779 / 07719 939900 / matt@thirdcity.co.uk

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release

Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E

Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release

Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye